Milestone Pharmaceuticals is trading 10.57% up at $1.15, with no confirmed company-specific catalyst explaining the August 25, 2026 move.
- The latest identified company announcement was the August 21 initiation of a pivotal Phase 3 etripamil trial for AFib-RVR; it predates today’s movement and does not establish direct causation.
- Broader markets are modestly higher, but gains remain below the threshold for attributing this move to overall market sentiment.